NCT04771611View on ClinicalTrials.gov

COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 14, 2021

Primary Completion Date

September 27, 2022

Study Completion Date

September 27, 2022

Conditions
Covid19Coronavirus Infection
Interventions
DRUG

Fisetin

\~20mg/kg /day oral for four days (days 0,1 and days 8,9)

DRUG

Placebo

Looks exactly like the study drug, but it contains no active ingredient . Oral for four days (days 0,1 and days 8,9)

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

James L. Kirkland, MD, PhD

OTHER